Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-06T09:47:48.698Z Has data issue: false hasContentIssue false

8 - Hematopoietic cell transplantation for non-Hodgkin lymphoma

Published online by Cambridge University Press:  05 August 2013

By
Saurabh Chhabra  and
Ginna G. Laport
Edited by
Reinhold Munker ,
Gerhard C. Hildebrandt ,
Hillard M. Lazarus  and
Kerry Atkinson
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Gerhard C. Hildebrandt
Affiliation:
University of Utah
Hillard M. Lazarus
Affiliation:
Ireland Cancer Center, Case Western Reserve University Hospital, Cleveland
Kerry Atkinson
Affiliation:
University of Queensland
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
The BMT Data Book
Including Cellular Therapy
 , pp. 90 - 112
Publisher: Cambridge University Press
Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alousi, AM, Saliba, RM, Okoroji, GJ, et al. 2008. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol 142: 786–792.CrossRefGoogle ScholarPubMed
Armitage, JO, Carbone, PP, Connors, JM, et al. 2003. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients. J Clin Oncol 21: 897–906.CrossRefGoogle ScholarPubMed
Ayala, E & Tomblyn, M. 2011. Hematopoietic cell transplantation for lymphomas. Cancer Control 18: 246–257.CrossRefGoogle ScholarPubMed
Baes, AH, Cao, Q, Wagner, JE, et al. 2010. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant 16: 287–291.Google Scholar
Balsalobre, P, Díez-Martin, JL, Re, A, et al. 2009. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol 27: 2192–2198.CrossRefGoogle ScholarPubMed
Biswas, T, Dhakal, S, Chen, R, et al. 2010. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era. Int J Rad Oncol Biol Phys 77: 79–85.CrossRefGoogle ScholarPubMed
Bouabdallah, R, Xerri, L, Bardou, VJ, et al. 1998. Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: a report on 62 patients from a single center. Ann Oncol 9: 619–625.CrossRefGoogle ScholarPubMed
Damon, LE, Johnson, JL, Niedzwiecki, D, et al. 2009. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 27: 6101–6108.CrossRefGoogle ScholarPubMed
d’Amore, F, Relander, T, Lauritzen, GF, et al. 2011. High-dose chemotherapy and autologous stem cell transplantation in previously untreated peripheral t-cell lymphoma – final analysis of a large prospective multicenter study (NLG-T-01). Blood 118: 331.Google Scholar
Determann, O, Hoster, E, Ott, G, et al. 2008. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 111: 2385–2387.CrossRefGoogle ScholarPubMed
Devetten, MP, Hari, PN, Carreras, J, et al. 2009. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 15: 109–117.CrossRefGoogle ScholarPubMed
Dodero, A, Crocchiolo, R, Patriarca, F, et al. 2010. Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation. Cancer 116: 5001–5011.CrossRefGoogle ScholarPubMed
Dodero, A, Spina, F, Narni, F, et al. 2012. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 26: 520–526.CrossRefGoogle ScholarPubMed
Dreyling, M. 2010. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21: S181–S183.CrossRefGoogle ScholarPubMed
El Gnaoui, T, Dupuis, J, Belhadj, K, et al. 2007. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 18: 1363–1368.CrossRefGoogle Scholar
Engels, EA, Biggar, RJ, Hall, HI, et al. 2008. Cancer risk in people infected with human immunodeficiency virus in the United States.Int J Cancer 123: 187–194.CrossRefGoogle ScholarPubMed
Filmont, JE, Gisselbrecht, C, Cuenca, X, et al. 2007. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 110: 1361–1369.CrossRefGoogle ScholarPubMed
Foss, FM, Zinzani, PL, Vose, JM, et al. 2011. Peripheral T-cell lymphoma. Blood 117: 6756–6767.CrossRefGoogle ScholarPubMed
Friedberg, JW. 2011. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011: 498–501.
Geisler, CH, Kolstad, A, Laurell, A, et al. 2008. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112: 2687–2693.CrossRefGoogle ScholarPubMed
Geisler, CH, Kolstad, A, Laurell, A, et al. 2010. The mantle cell lymphoma international prognostic index (MIPI) is superior to the international prognostic index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 115: 1530–1533.CrossRefGoogle Scholar
Ghielmini, M & Zucca, E. 2009. How I treat mantle cell lymphoma. Blood 114: 1469–1476.CrossRefGoogle Scholar
Gisselbrecht, C, Glass, B, Mounier, N, et al. 2010. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28: 4184–4190.CrossRefGoogle ScholarPubMed
Goldberg, JD, Chou, JF, Horwitz, S, et al. 2012. Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant. Leuk Lymphoma 53: 1124–1129.
Gross, TG, Hale, GA, He, W, et al. 2010. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant 16: 223–230.CrossRefGoogle ScholarPubMed
Gyan, E, Foussard, C, Bertrand, P, et al. 2009. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 113: 995–1001.CrossRefGoogle ScholarPubMed
Hamlin, PA, Zelenetz, AD, Kewalramani, T, et al. 2003. Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 102: 1989–1996.CrossRefGoogle ScholarPubMed
Hari, PN, Majhail, NS, Zhang, MJ, et al. 2010. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 16: 395–402.CrossRefGoogle ScholarPubMed
Hoelzer, D, Gokbuget, N, Digel, W, et al. 2002. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 99: 4379–4385.CrossRefGoogle ScholarPubMed
Hoster, E, Dreyling, M, Klapper, W, et al. 2008. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111: 558–565.CrossRefGoogle ScholarPubMed
Jacobsen, ED, Kim, HT, Ho, VT, et al. 2011. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol 22: 1608–1613.CrossRefGoogle ScholarPubMed
Kewalramani, T, Zelenetz, AD, Nimer, SD, et al. 2004. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103: 3684–3688.CrossRefGoogle ScholarPubMed
Khouri, I, Saliba, RM, Valverde, R, et al. 2011. Nonmyeloablative allogeneic stem cell transplantation with or without 90yttrium ibritumomab tiuxetan (90YIT) is curative for relapsed follicular lymphoma: median 9 year follow-up results. Blood 118: 662.Google Scholar
Krishnan, A, Molina, A, Zaia, J, et al. 2005. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 105: 874–878.CrossRefGoogle ScholarPubMed
Kroger, N, Hoffknecht, M, Dreger, P, et al. 1998. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant 21: 55–57.CrossRefGoogle ScholarPubMed
Kyriakou, C, Canals, C, Finke, J, et al. 2009. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 27: 3951–3958.CrossRefGoogle ScholarPubMed
Lacasce, A, Howard, O, Lib, S, et al. 2004. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma 45: 761–767.CrossRefGoogle ScholarPubMed
Lambert, JR, Bomanji, JB, Peggs, KS, et al. 2010. Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood 115: 2763–2768.CrossRefGoogle ScholarPubMed
Landgren, O, Gilbert, ES, Rizzo, JD, et al. 2009. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 113: 4992–5001.CrossRefGoogle ScholarPubMed
Laudi, N, Arora, M, Burns, L, et al. 2006. Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma. Am J Hematol 81: 519–524.CrossRefGoogle ScholarPubMed
Lazarus, HM, Zhang, MJ, Carreras, J, et al. 2010. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant 16: 35–45.CrossRefGoogle ScholarPubMed
Leisenring, W, Friedman, DL, Flowers, ME, et al. 2006. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 24: 1119–1126.CrossRefGoogle ScholarPubMed
Lenz, G, Dreyling, M, Schiegnitz, E, et al. 2004. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104: 2667–2674.CrossRefGoogle ScholarPubMed
Levine, JE, Harris, RE, Loberiza, FR, et al. 2003. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 101: 2476–2482.CrossRefGoogle ScholarPubMed
Linch, DC. 2012. Burkitt lymphoma in adults. Br J Haematol 156: 693–703.CrossRefGoogle ScholarPubMed
Lim, ST, Karim, R, Nathwani, BN, et al. 2005. AIDS-related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 23: 4430–4438.CrossRefGoogle ScholarPubMed
Lopez, A, Gutierrez, A, Palacios, A, et al. 2008. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol 80: 127–132.CrossRefGoogle ScholarPubMed
Loren, AW, Chow, E, Jacobsohn, DA, et al. 2011. Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant 17: 157–166.CrossRefGoogle Scholar
Maris, MB, Sandmaier, BM, Storer, BE, et al. 2004. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104: 3535–3542.CrossRefGoogle ScholarPubMed
Mercadal, S, Briones, J, Xicoy, B, et al. 2008. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19: 958–963.CrossRefGoogle ScholarPubMed
Metayer, C, Curtis, RE, Vose, J, et al. 2003. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 101: 2015–2023.CrossRefGoogle ScholarPubMed
Nademanee, A, Forman, S, Molina, A, et al. 2005. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106: 2896–2902.CrossRefGoogle ScholarPubMed
Numata, A, Miyamoto, T, Ohno, Y, et al. 2010. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant 45: 311–316.CrossRefGoogle ScholarPubMed
Oehler-Janne, C, Taverna, C, Stanek, N, et al. 2008. Consolidative involved field radiotherapy after high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin’s lymphoma: a case-control study. Hematol Oncol 26: 82–90.CrossRefGoogle ScholarPubMed
Palmer, J, Goggins, T, Broadwater, G, et al. 2011.Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant 46:847–851.CrossRefGoogle Scholar
Pasquini, MC & Wang, Z. 2011. Current use and outcome of hematopoietic stem cell transplantation. CIBMTR Summary Slides.Google Scholar
Peniket, AJ, Ruiz de Elvira, MC, Taghipour, G, et al. 2003. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31: 667–678.CrossRefGoogle ScholarPubMed
Philip, T, Guglielmi, C, Hagenbeek, A, et al. 1995. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333: 1540–1545.CrossRefGoogle ScholarPubMed
Pinana, JL, Martino, R, Gayoso, J, et al. 2010. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica 95: 1176–1182.CrossRefGoogle ScholarPubMed
Press, OW, Eary, JF, Gooley, T, et al. 2000. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96: 2934–2942.Google Scholar
Reddy, N, Rezvani, K, Barrett, AJ, et al. 2011. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant 17: 591–597.CrossRefGoogle ScholarPubMed
Reimer, P, Rudiger, T, Geissinger, E, et al. 2009. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27: 106–113.CrossRefGoogle ScholarPubMed
Rodriguez, J, Conde, E, Gutierrez, A, et al. 2007. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 18: 652–657.CrossRefGoogle ScholarPubMed
Romaguera, JE, Fayad, LE, Feng, L, et al. 2010. Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haem 150: 200–208.Google ScholarPubMed
Savage, KJ & Gregory, SA. 2010. Lymphomas. American Society of Hematology-Self Assessment Program, Chapter 18, pp. 511–554.
Sebban, C, Mounier, N, Brousse, N, et al. 2006. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 108: 2540–2544.CrossRefGoogle Scholar
Sehn, LH, Berry, B, Chhanabhai, M, et al. 2007. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109: 1857–1861.CrossRefGoogle Scholar
Shea, T, Johnson, J, Westervelt, P, et al. 2011. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant 17: 1395–1403.CrossRefGoogle ScholarPubMed
Shipp, MA, Harrington, DP, Andersen, JR, et al. 1993. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329: 987–994.Google Scholar
Solal-Celigny, P, Roy, P, Colombat, P, et al. 2004. Follicular lymphoma international prognostic index. Blood 104: 1258–1265.CrossRefGoogle ScholarPubMed
Song, KW, Barnett, MJ, Gascoyne, RD, et al. 2007. Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. Ann Oncol 18: 535–540.CrossRefGoogle ScholarPubMed
Stiff, PJ, Unger, JM, Cook, J, et al. 2011. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). J Clin Oncol 29: S8001.CrossRefGoogle Scholar
Swerdlow, SH, Campo, E, Harris, NL, et al. 2008. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. 4th edn. Lyon: IARC Press.Google Scholar
Tam, CS, Bassett, R, Ledesma, C, et al. 2009. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113: 4144–4152.CrossRefGoogle Scholar
Thomas, DA, Faderl, S, O’Brien, S, et al. 2006. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106: 1569–1580.CrossRefGoogle ScholarPubMed
Thomas, DA, O’Brien, S, Cortes, J, et al. 2004. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 104: 1624–1630.CrossRefGoogle ScholarPubMed
Thompson, LA, Guthrie, KA, Budde, LE, et al. 2011. The pre-transplant mantle cell lymphoma international prognostic index predicts overall and progression-free survival following high-dose therapy and autologous stem cell transplant for mantle cell lymphoma. Blood 118: 2026.Google Scholar
Tilly, H & Dreyling, M. 2010. Diffuse large B-cell non-Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21: S172–S174.CrossRefGoogle ScholarPubMed
van Esser, JW, Niesters, HG, van der Holt, B, et al. 2002. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99: 4364–4369.CrossRefGoogle ScholarPubMed
van Kampen, RJ, Canals, C, Schouten, HC, et al. 2011. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 29: 1342–1348.CrossRefGoogle Scholar
Vose, JM, Bierman, PJ, Enke, C, et al. 2005. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin’s lymphoma. J Clin Oncol 23: 461–467.CrossRefGoogle ScholarPubMed
Vose, JM, Carter, SL, Burns, LJ, et al. 2011. Randomized phase III trial of 131-iodine-tositumomab (Bexxar)/carmustine, etoposide, cytarabine, melphalan (BEAM) vs. rituximab/BEAM and autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): no difference in progression-free (PFS) or overall survival (OS). Blood 118: 661.Google Scholar
Vose, JM, Rizzo, DJ, Tao-Wu, J, et al. 2004. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant 10: 116–127.CrossRefGoogle ScholarPubMed
Vose, JM, Zhang, MJ, Rowlings, PA, et al. 2001. Autologous transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 19: 406–413.CrossRefGoogle ScholarPubMed
Zelenetz, A, Abramson, JS, Advani, A, et al. 2012. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin’s Lymphomas. NCCN, Ver 2. Available at: .Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×